They match their therapeutic candidates to specific molecular abnormalities found in patients with high clinical need and have a diverse pipeline that includes monoclonal antibodies, recombinant proteins, and gene therapies. With funding from leading life science investors and academic partnerships worldwide, Gemini Therapeutics is developing a series of potentially groundbreaking therapeutics for these conditions.